Indonesia’s stocks slid and credit default swaps tracking the nation’s sovereign debt widened the most in over four months after Moody’s Ratings lowered its outlook on the nation’s credit to negative. Stocks tumbled as much as 2.7% while the cost to insure Indonesian debt against default climbed by 4.3 basis points to around 80 basis points on Friday, the biggest increase among Asian sovereigns, a...
Indonesia’s stocks slid and credit default swaps tracking the nation’s sovereign debt widened the most in over four months after Moody’s Ratings lowered its outlook on the nation’s credit to negative. Stocks tumbled as much as 2.7% while the cost to insure Indonesian debt against default climbed by 4.3 basis points to around 80 basis points on Friday, the biggest increase among Asian sovereigns, according to a trader. If the move holds, that would be the most widening since late September, according to data compiled by Bloomberg. Meanwhile, the rupiah fell as much as 0.3% to 16,885. While Moody’s reaffirmed Indonesia’s Baa2 rating, the outlook cut from stable indicates that the rating may be downgraded if the government doesn’t take sufficient steps to address fiscal pressures, a weakening in foreign reserves and debt concerns related to state-owned firms, it said in a statement on Thursday. The outlook cut came just a week after index provider MSCI Inc. warned that Indonesia could be downgraded to frontier status because of a lack of liquidity and transparency in the stock market, triggering a massive equities selloff. It underscores the challenges President Prabowo Subianto’s administration faces as it tries to restore market confidence. Policymakers rushed to respond on Thursday. Bank Indonesia Governor Perry Warjiyo said in a statement that the outlook downgrade “does not reflect any weakening in Indonesia’s economic fundamentals.” The Finance Ministry pledged to continue to transform the economy and revive growth engines while ensuring that “every potential risk will be properly managed.” Moody’s Warning Puts Indonesia’s Policy Choices Under Scrutiny Investors See Higher Risk Premium From Moody’s Indonesia Outlook
IREN NASDAQ: IREN used its fiscal second-quarter 2026 earnings call to emphasize progress in its shift from Bitcoin mining to what management described as a vertically integrated AI cloud platform, highlighting new GPU financing commitments, additional secured power capacity, and continued customer engagement for both current and prior-generation GPUs. Get IREN alerts: Sign Up Financing package ti...
IREN NASDAQ: IREN used its fiscal second-quarter 2026 earnings call to emphasize progress in its shift from Bitcoin mining to what management described as a vertically integrated AI cloud platform, highlighting new GPU financing commitments, additional secured power capacity, and continued customer engagement for both current and prior-generation GPUs. Get IREN alerts: Sign Up Financing package tied to Microsoft contract Co-founder and Co-CEO Daniel Roberts said the company secured underwriting commitments for $3.6 billion of GPU financing at an interest rate expected to be less than 6%. Management said that, when combined with $1.9 billion in customer prepayments from Microsoft, the package covers approximately 95% of the GPU-related capital expenditures supporting IREN’s $9.7 billion AI contract with Microsoft. CFO Anthony Lewis described the facility as a delayed-draw term loan from Goldman Sachs and J.P. Morgan structured to align with IREN’s CapEx profile. Lewis said it amortizes in full over a five-year term, and is secured against both the GPUs and the contracted cash flows from Microsoft, which management said supports the facility’s credit profile and pricing. Roberts argued that the financing reduces a key concern around AI cloud—GPU capital intensity—and said that when factoring in the Microsoft prepayment, the company views its average interest cost as “around 3%.” He added that the financing outcome provides clarity to advance broader customer discussions. Capacity build-out and expanding power portfolio Roberts and Chief Commercial Officer Kent Draper framed IREN’s scale-up strategy around “capacity, customers, and capital,” saying the three elements are moving in parallel. Draper said IREN designs, builds, and operates its own data centers, supported by internal engineering, procurement, construction, technology, and operations teams, which management positioned as an advantage amid industry constraints such as long-lead equipment and skilled labor av...
How To Feel Joy In A Dopamine-Saturated World Authored by Sheridan Genrich via The Epoch Times (emphasis ours), Your brain treats what it sees in Instagram reels the same way it treats cocaine . Both experiences flood a thumbnail-sized region of the brain with dopamine—a chemical that makes you want more, right now. The problem is that after a certain amount of dopamine hits, your brain adapts by ...
How To Feel Joy In A Dopamine-Saturated World Authored by Sheridan Genrich via The Epoch Times (emphasis ours), Your brain treats what it sees in Instagram reels the same way it treats cocaine . Both experiences flood a thumbnail-sized region of the brain with dopamine—a chemical that makes you want more, right now. The problem is that after a certain amount of dopamine hits, your brain adapts by turning down the pleasure volume . As a result, things that once made you feel good are no longer enough. Vink Fan/Shutterstock If you’re finding it harder to feel simple joy and genuine connections, you’re experiencing what addiction psychiatrists now recognize as dopamine overload, a state where constant stimulation—especially from cellphones, social media, and ultra-processed foods—quietly erodes your ability to feel your happiest emotions and leaves relationships feeling painfully empty. However, there is hope—through learning to rebalance our reward systems, we can rediscover contentment in simple things. The Dopamine Hijack Dopamine is a brain chemical messenger that helps drive motivation, heightens anticipation, and reinforces the experiences your brain labels as rewarding. In healthy balance, it nudges us toward naturally meaningful activities—such as working toward goals, sharing meals, spending time with friends—that have long supported survival and human connection. However, modern life delivers dopamine in doses and speeds the human brain is not equipped to handle. “Things that are addictive release a whole lot of dopamine all at once in a part of the brain called the nucleus accumbens,” Addiction psychiatrist and author Dr. Anna Lembke, a leading voice on how modern habits hijack the brain’s reward circuitry, told The Epoch Times. “The more dopamine that is released there, and the faster it is released, the more likely we see addictive behavior.” * * * Get 30% off in February on Peak Focus ! With long-term exposure to highly addictive substances and behaviors...
Earnings Call Insights: Hub Group (HUBG) Q4 2025 Management View Phillip Yeager, President, CEO & Vice Chairman of the Board, opened the call by addressing an identified calculation error that led to the understatement of purchase transportation costs and accounts payable, resulting in a delay in finalizing Q4 and full year 2025 financial results. He stated, "Accuracy and transparency in reporting...
Earnings Call Insights: Hub Group (HUBG) Q4 2025 Management View Phillip Yeager, President, CEO & Vice Chairman of the Board, opened the call by addressing an identified calculation error that led to the understatement of purchase transportation costs and accounts payable, resulting in a delay in finalizing Q4 and full year 2025 financial results. He stated, "Accuracy and transparency in reporting on our performance is of the utmost importance at Hub Group, and we have taken steps to strengthen and enhance our controls." Yeager noted, "The last year was a continuation of a challenging market cycle with stable demand and an oversupply of capacity. We performed well and focused on controlling what we can control, delivering record service levels across our platform and in particular, our Intermodal segment, while managing our costs, adding new business wins and investing in our business, including equipment, technology and acquisitions." Intermodal volumes increased 1% year-over-year in Q4, with revenue per load flat but up 3% sequentially. Refrigerated volumes rose 150% and Mexico volumes increased 33%. Yeager highlighted, "We worked extremely well with our rail partners during peak, delivering a 90 basis point improvement in year-over-year on-time performance, positioning us well for Intermodal volume growth in 2026 bid season." In Dedicated, revenue declined in Q4 due to lost sites earlier in the year, but operational discipline and improved service levels created a strong pipeline of growth opportunities. Logistics segment revenue for Q4 reflected softer demand but was partially offset by new business wins. Warehouse consolidation led to a 630 basis point improvement in space utilization year-over-year. In Final Mile, onboarding of significant new business wins is ongoing, with investments made to ensure a seamless transition, although Q4 volume underperformed due to onboarding delays and minor scope changes. Brokerage volumes declined 10% year-over-year in Q4, wi...
(RTTNews) - Pfizer Inc. (PFE) announced the launch of its TrumpRx program, designed to make innovative medicines more affordable and accessible to millions of Americans. Through this initiative, more than 30 primary care and specialty treatments will be offered at significant discounts—averaging 50% and reaching as high as 85%—for patients who choose to self-pay outside of insurance. The program, ...
(RTTNews) - Pfizer Inc. (PFE) announced the launch of its TrumpRx program, designed to make innovative medicines more affordable and accessible to millions of Americans. Through this initiative, more than 30 primary care and specialty treatments will be offered at significant discounts—averaging 50% and reaching as high as 85%—for patients who choose to self-pay outside of insurance. The program, part of Pfizer's landmark Most Favored Nation (MFN) agreement with the U.S. government, aims to lower prescription costs for conditions affecting over 100 million people, including migraines, rheumatoid arthritis, menopause, atopic dermatitis, and overactive bladder. Pfizer is also partnering with GoodRx to provide patients greater flexibility, enabling them to use coupons at nearly any U.S. pharmacy or opt for select at-home delivery options. PFE closed regular trading at $26.49, down $0.29 or 1.08%. In overnight trading, the stock slipped slightly to $26.44, down $0.05 or 0.19%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image source: The Motley Fool. Feb. 5, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Chad Robins Chief Financial Officer — Kyle Piskel Chief Commercial Officer — Susan Bobulsky Chief Business Development and Partnerships Officer — Sharon Benzeno Takeaways Total company revenue -- $277 million for 2025, up 55% year over year, including 51% growth to $71.7 million in the fourth qu...
Image source: The Motley Fool. Feb. 5, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Chad Robins Chief Financial Officer — Kyle Piskel Chief Commercial Officer — Susan Bobulsky Chief Business Development and Partnerships Officer — Sharon Benzeno Takeaways Total company revenue -- $277 million for 2025, up 55% year over year, including 51% growth to $71.7 million in the fourth quarter. -- $277 million for 2025, up 55% year over year, including 51% growth to $71.7 million in the fourth quarter. MRD revenue -- $212 million in 2025, increasing 46% with clinical clonoSEQ testing revenue up 64% and pharma MRD business up 20%, including $19.5 million in milestone revenue. -- $212 million in 2025, increasing 46% with clinical clonoSEQ testing revenue up 64% and pharma MRD business up 20%, including $19.5 million in milestone revenue. clonoSEQ test volume -- 30,038 tests performed in Q4, up 43% year over year and 11% sequentially, with annual volume growth supported by multiple myeloma at 44% of U.S. tests. -- 30,038 tests performed in Q4, up 43% year over year and 11% sequentially, with annual volume growth supported by multiple myeloma at 44% of U.S. tests. Blood-based testing mix -- 47% of clonoSEQ tests used blood in Q4, rising 6 percentage points year over year, with multiple myeloma blood-based testing reaching 27%. -- 47% of clonoSEQ tests used blood in Q4, rising 6 percentage points year over year, with multiple myeloma blood-based testing reaching 27%. Average selling price (ASP) -- U.S. ASP ended the year at $1,307 per clonoSEQ test, up 17% year over year, exiting Q4 at roughly $1,350; 2026 ASP targeted at $1,400. -- U.S. ASP ended the year at $1,307 per clonoSEQ test, up 17% year over year, exiting Q4 at roughly $1,350; 2026 ASP targeted at $1,400. Commercial payer collections -- Improved 74% year over year, driven by contract renegotiations and operational enhancements. -- Improved 74% year over year, driven by contract renegotiations and opera...
Cantor Fitzgerald noted that Amazon’s $200 billion capital expenditure plans could reignite concerns around long-term return on invested capital. Amazon store is seen at Promenade Street in Davos, Switzerland on January 21, 2025. (Photo by Ömer Sercan Karku/Anadolu via Getty Images) Cantor Fitzgerald lowered Amazon’s price target to $250 and maintained an ‘Overweight’ rating. TD Cowen cut Amazon’s...
Cantor Fitzgerald noted that Amazon’s $200 billion capital expenditure plans could reignite concerns around long-term return on invested capital. Amazon store is seen at Promenade Street in Davos, Switzerland on January 21, 2025. (Photo by Ömer Sercan Karku/Anadolu via Getty Images) Cantor Fitzgerald lowered Amazon’s price target to $250 and maintained an ‘Overweight’ rating. TD Cowen cut Amazon’s price target to $300, kept a ‘buy’ rating, and said investors will focus on its record capital spending. Amazon expects first-quarter revenue to grow between 11% and 15%. Shares of Amazon.com Inc (AMZN) slumped nearly 8% in premarket trading on Friday, as analysts raised concerns over the company’s massive capital expenditure plans for 2026, on the back of an earnings miss in the fourth quarter. AMZN stock extended losses from Thursday, when it closed 4.4% lower, and fell below its 200-day moving average (200-DMA) for the first time since Oct. 20, 2025. It was also the stock’s biggest intraday decline in more than two months. Source: TradingView If the pre-market level holds, the stock will open at its lowest levels since June 4, 2025. Massive Capex Spend On Thursday, Amazon reported earnings per share of $1.95, up from $1.86 a year earlier but slightly below analyst expectations of $1.97, according to Stocktwits data. Revenue rose 14% to $213.4 billion, topping the Street’s estimate of $211.44 billion. Going forward, the company expects revenue for the first quarter (Q1) of FY2026 to grow between 11% and 15%, while operating income is projected between $16.5 billion and $21.5 billion, compared with $18.4 billion in the same period last year. One of the key highlights was Amazon announcing a more than 50% increase in capital expenditure for 2026, allocating $200 billion for what the management described as “strong demand for our existing offerings and seminal opportunities like AI, chips, robotics, and low-earth orbit satellites.” Concerns Around Long-term Return Cantor Fi...